In contrast, the development and preclinical evaluation of new PSMA ligands which could be labeled with therapeutic radionuclides such as 177Lu, paved the way for the reinvestigation of the 177Lu-based radionuclide therapy in patients with advanced prostate cancer. Here, FOLH1 is linked to prostate carcinoma.